Literature DB >> 11168556

LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10.

E Molina-Holgado1, J M Vela, A Arévalo-Martín, C Guaza.   

Abstract

Proinflammatory mediators have been implicated in demyelinating disorders, including multiple sclerosis, whereas it has been proposed that the anti-inflammatory cytokines interleukin- (IL-) 4 and IL-10 participate in disease recovery. The present study analysed the effect of interferon-gamma (IFN-gamma) and bacterial endotoxin (lipopolysaccharide, LPS) on proliferation and survival of progenitors and differentiated oligodendrocytes. We also investigated the presence of receptors for IL-4 and IL-10 in oligodendroglial cells and explored a possible protective action of IL-4 and IL-10 in cultures following LPS/IFN-gamma. Finally, the role of endogenous nitric oxide (NO) on cell viability and the modulatory action of IL-4 and IL-10 on inducible nitric oxide synthase (iNOS) expression were also analysed. We report that LPS and/or IFN-gamma reduced proliferation and viability of oligodendroglial cells. Cell death, presumably by apoptosis as evidence by TUNEL and Annexin V binding, was observed following LPS/IFN-gamma, progenitors being more sensitive than differentiated cells. At both developmental stages, LPS/IFN-gamma-treated cultures expressed iNOS protein and released micromolar concentrations of NO. In progenitors, LPS/IFN-gamma-mediated cell damage was partially dependent on endogenous NO production, whereas NO was fundamental for cytotoxicity of differentiated oligodendrocytes. Both cell types expressed mRNA for IL-4 and IL-10 receptors and expression of IL-10 receptors at the protein level was also demonstrated. Treatment with either cytokine inhibited the expression of iNOS resulting from the proinflammatory stimulation. IL-10 was more effective than IL-4 in suppressing iNOS expression and, interestingly, IL-10 conferred protection against oligodendroglial death evoked by LPS/IFN-gamma. Our data raise the question of whether IL-10 may play a protective role in demyelinating diseases, not only downregulating the function of inflammatory cells but also promoting survival of progenitors and differentiated oligodendrocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168556     DOI: 10.1046/j.0953-816x.2000.01412.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  46 in total

1.  Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium.

Authors:  Prasanna Krishnamurthy; Melissa Thal; Suresh Verma; Eneda Hoxha; Erin Lambers; Veronica Ramirez; Gangjian Qin; Douglas Losordo; Raj Kishore
Journal:  Circ Res       Date:  2011-09-29       Impact factor: 17.367

2.  In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes.

Authors:  S Y Yao; A Ljunggren-Rose; N Chandramohan; W O Whetsell; S Sriram
Journal:  J Neuroimmunol       Date:  2010-08-19       Impact factor: 3.478

3.  Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice.

Authors:  S Takagi; N Hayakawa; H Kimoto; H Kato; T Araki
Journal:  J Neural Transm (Vienna)       Date:  2007-08-06       Impact factor: 3.575

4.  Interleukin-10/Ceftriaxone prevents E. coli-induced delays in sensorimotor task learning and spatial memory in neonatal and adult Sprague-Dawley rats.

Authors:  K L Wallace; J Lopez; J P Shaffery; A Wells; I A Paul; W A Bennett
Journal:  Brain Res Bull       Date:  2010-01-15       Impact factor: 4.077

5.  A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.

Authors:  Aitor G Granja; Francisco Carrillo-Salinas; Alberto Pagani; María Gómez-Cañas; Roberto Negri; Carmen Navarrete; Miriam Mecha; Leyre Mestre; Bend L Fiebich; Irene Cantarero; Marco A Calzado; Maria L Bellido; Javier Fernandez-Ruiz; Giovanni Appendino; Carmen Guaza; Eduardo Muñoz
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-14       Impact factor: 4.147

6.  Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

Authors:  Angel Arévalo-Martín; José Miguel Vela; Eduardo Molina-Holgado; José Borrell; Carmen Guaza
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 7.  CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.

Authors:  A Arévalo-Martín; D García-Ovejero; O Gómez; A Rubio-Araiz; B Navarro-Galve; C Guaza; E Molina-Holgado; F Molina-Holgado
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

8.  Impact of indolent inflammation on neonatal hypoxic-ischemic brain injury in mice.

Authors:  John D E Barks; Yi-Qing Liu; Yu Shangguan; Joyce Li; Jennifer Pfau; Faye S Silverstein
Journal:  Int J Dev Neurosci       Date:  2007-08-22       Impact factor: 2.457

9.  Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis.

Authors:  Ajaib Singh Paintlia; Manjeet Kaur Paintlia; Avtar Kaur Singh; Inderjit Singh
Journal:  Mol Pharmacol       Date:  2008-01-31       Impact factor: 4.436

10.  Interleukin-10: a key cytokine in depression?

Authors:  Susana Roque; Margarida Correia-Neves; Ana Raquel Mesquita; Joana Almeida Palha; Nuno Sousa
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.